No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.

Détails

Cette publication est une ancienne version. Cette notice est remplacée par serval:BIB_4A53A3D43CC0
Ressource 1 Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_683DA0C4D026
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Périodique
BMC research notes
Auteur⸱e⸱s
Claude F., Rochat I., Hafen G.M.
ISSN
1756-0500 (Electronic)
ISSN-L
1756-0500
Statut éditorial
Publié
Date de publication
04/03/2019
Peer-reviewed
Oui
Volume
12
Numéro
1
Pages
115
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months' period.
Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
Mots-clé
Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/pharmacology, Child, Ciprofloxacin/administration & dosage, Ciprofloxacin/pharmacology, Clinical Protocols, Cystic Fibrosis/complications, Female, Humans, Male, Outcome and Process Assessment (Health Care), Pseudomonas Infections/drug therapy, Pseudomonas Infections/etiology, Pseudomonas aeruginosa/drug effects, Retrospective Studies, Time Factors, Tobramycin/administration & dosage, Tobramycin/pharmacology, Cystic fibrosis, Eradication protocol, Primoinfection, Pseudomonas aeruginosa
Pubmed
Open Access
Oui
Création de la notice
07/04/2019 15:10
Dernière modification de la notice
30/10/2023 9:57
Données d'usage